N-(alpha-Ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential antipsychotic drug for the treatment of schizophrenia.